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In higher eukaryotic genomes, Long Interspersed Nuclear Element 1 (LINE-1)
retrotransposons represent a large family of repeated genomic elements. They transpose
using a reverse transcriptase (RT), which they encode as part of the ORF2p product.
RT inhibition in cancer cells, either via RNA interference-dependent silencing of active
LINE-1 elements, or using RT inhibitory drugs, reduces cancer cell proliferation, promotes
their differentiation and antagonizes tumor progression in animal models. Indeed, the
non-nucleoside RT inhibitor efavirenz has recently been tested in a phase II clinical trial
with metastatic prostate cancer patients. An in-depth analysis of ORF2p in a mouse
model of breast cancer showed ORF2p to be precociously expressed in precancerous
lesions and highly abundant in advanced cancer stages, while being barely detectable in
normal breast tissue, providing a rationale for the finding that RT-expressing tumors are
therapeutically sensitive to RT inhibitors. We summarize mechanistic and gene profiling
studies indicating that abundant LINE-1-derived RT can “sequester” RNA substrates for
reverse transcription in tumor cells, entailing the formation of RNA:DNA hybrid molecules
and impairing the overall production of regulatory miRNAs, with a global impact on the cell
transcriptome. Based on these data, LINE-1-ORF2 encoded RT has a tumor-promoting
potential that is exerted at an epigenetic level. We propose a model whereby LINE1-RT
drives a previously unrecognized global regulatory process, the deregulation of which
drives cell transformation and tumorigenesis with possible implications for cancer cell
heterogeneity.
Keywords: LINE-1 retrotransposons, reverse transcriptase, tumorigenesis, differentiation therapy, cancer
heterogeneity, epigenetics
INTRODUCTION: THE RETROTRANSPOSITION MACHINERY IN
THE GENESIS OF GENOMIC AND EPIGENOMIC LANDSCAPES
The complete sequencing of the human genome has disclosed the unexpected finding that coding
genes account for a mere 1.2% of the total genome, while the remaining portion is constituted by
non-coding DNA (International Human Genome Sequencing Consortium, 2001). Branded by a
historically “bad reputation”, non-coding sequences have been defined as “junk” (Ohno, 1972) or
“selfish” (Orgel and Crick, 1980) DNA, a view further strengthened by the evidence that nearly 50%
of the human genome is constituted by apparently functionless transposable “genetic parasites”
thought to increasingly litter all chromosomes during evolution.
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Two main families of transposable elements characterize
eukaryotic genomes: DNA transposons, which mobilize through
a “cut and paste” mechanism (Muñoz-López and García-Pérez,
2010), and retrotransposons, which mobilize instead through
“copy and paste,” a process that requires the reverse transcription
of RNA intermediates into cDNA copies as a preliminary step
in retrotransposition (Levin and Moran, 2011), promoting the
broad expansion of retroelements in eukaryotic genomes.
A key player in this mechanism is the enzyme reverse
transcriptase (RT) encoded by LINE-1 retrotransposons
themselves. The latter are a source of the RT activity required
to promote retrotransposition in human cells (Brouha et al.,
2003). LINE-1 elements actually harbor two open reading
frames, ORF1 and ORF2, which respectively encode ORF1p, an
RNA-binding protein, and ORF2p, with reverse transcriptase
(RT) and endonuclease (EN) activities (reviewed in Babushok
and Kazazian, 2007). The LINE-1-derived retrotransposition
machinery, constituted by ORF1 and ORF2 proteins, has
cis-preference for its own LINE-1 RNA (Esnault et al., 2000;
Wei et al., 2001; Kulpa and Moran, 2006). LINE-1-derived
RT is also used for retrotranscription /retrotransposition of
other RNAs, including Alu elements (Dewannieux et al., 2003),
SVA (SINE-R/VNTR/ALU) elements (Ostertag et al., 2003)
and mRNAs that give rise to a large population of processed
pseudogenes nearly as numerous as the original coding genes
(Pink et al., 2011). It is now well established that RT-originating
sequences contribute to shape genomes and constitute a large
proportion of evolutionarily conserved chromosomal DNA,
accounting altogether for nearly 50% of the human genome
(International Human Genome Sequencing Consortium, 2001).
Such extensive preservation suggests a functional importance
of retrotransposons. Not surprisingly, retrotransposons are
increasingly being implicated in fundamental genomic functions,
in both normal and pathological contexts (Rebollo et al., 2012).
Indeed, as highly dynamic components of genomes, they
contribute a relentless source of genetic and epigenetic variations
and novelty (Feschotte, 2008; Bourque, 2009; Beck et al.,
2011) and, on the long run, a major driving force in genome
evolution (Oliver and Greene, 2011). A detailed description of all
functional implications of retrotransposition in genome biology
and evolution would be out of scope in this article, but extensive
information is discussed in excellent reviews (Feschotte, 2008;
Goodier and Kazazian, 2008; Bourque, 2009; Beck et al., 2011;
Oliver and Greene, 2011; Rebollo et al., 2012).
The advent of high-throughput technologies in recent years
has provided an accurate localization of new genomic insertions,
shifting the focus from a gene-centric to a genome-wide view.
This has revolutionized the traditional paradigms of genome
organization by disclosing novel and unexpectedly complex
genomic landscapes. Studies now show that genomes are
crowded with sequences of reverse-transcribed origin, many
of which are correlated with the insurgence of a variety of
pathologies (for a review Hancks and Kazazian, 2012), in
particular cancer (Belancio et al., 2010).
The ENCODE Project Consortium (The ENCODE Project
Consortium, 2012) showed that approximately 80% of the human
genome is pervasively transcribed; actually, a relevant proportion
of small and long non-coding transcripts are functional
components of genome-wide regulatory networks (Djebali et al.,
2012). The groundbreaking finding of an astounding landscape
of small RNAs—classified as microRNAs (miRNAs), endogenous
small interfering RNAs (endo-siRNAs or siRNAs) (Piatek and
Werner, 2014) and Piwi-interacting RNAs (piRNAs) (Kim et al.,
2009), depending on their origin and the proteins they interact
with - has unveiled an RNA-mediated regulatory network that
controls the genome architecture and transcriptomic profile
(Aalto and Pasquinelli, 2012; Li, 2014), influencing a multitude
of biological processes. Growing data show a dual relationship
between small RNAs and retroelements: on the one hand, small
RNAs act as “guardians of the genome” in transposon-defense
pathways aimed at repressing retroelement mobility (Yang and
Kazazian, 2006; reviewed in Malone and Hannon, 2009); on
the other hand, retroelements are intimately involved in their
biogenesis, because a growing number of small RNAs in all
three classes have a recognized retrotransposon-derived origin
(Borchert et al., 2011; Watanabe et al., 2011).
Long non-coding RNA (lncRNAs) are components of the
mammalian transcriptome and constitute a heterogeneous
class of thousands of polymerase II-transcribed RNA species,
polyadenylated, spliced, mostly localized in the nucleus (reviewed
by Zhang et al., 2013). A large proportion of lncRNAs, with
either oncogenic or tumor suppressor roles, are constituted
by antisense RNAs; the latter, together with sense transcripts,
are being identified in genome-wide regulatory networks that
epigenetically fine-tune genome expression, with implications
in tumorigenesis, differentiation and development (reviewed
in Pelechano and Steinmetz, 2013, Fatica and Bozzoni, 2014).
lncRNAs also have tight connections with transposable elements
of both the DNA-based and the retroelements families,
which occur within nearly 80% of mature lncRNA transcripts
and account for about 30–40% of total human lncRNA
sequences (Kelley and Rinn, 2012; Kapusta et al., 2013).
Also of RT-derived origin are a large proportion of genomic
sequences highly preserved throughout evolution and classified
as conserved, highly-conserved and ultra-conserved elements
(UCRs), according to the level of conservation throughout
species (Bejerano et al., 2004; Woolfe et al., 2005, for a recent
review see Nelson and Wardle, 2013).
From an ample survey encompassing the genomes of 29
mammalian species (Lowe and Haussler, 2012), a vision of
genomes emerges as complex integrated functional systems, in
which a considerable proportion of non-exonic sequences were
exapted from mobile element insertions (Nishihara et al., 2006;
Lowe and Haussler, 2012) to assemble large-scale regulatory
circuits. Deregulation of these circuits is implicated in a variety
of diseases, including cancer (Esteller, 2011).
LINE-1-ENCODED RT AS A NEW
UNDERESTIMATED PLAYER IN CANCER
While retrotransposable elements are extensively studied and
characterized, somewhat surprisingly the retrotransposon-
encoded RT activity has long failed to attract an equivalent
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attention. The RT encoded by infective retroviruses has actually
been intensively studied since the time of its discovery in 1970
by Baltimore (1970) and Temin and Mizutani (1970), due
to its clinical implications (Herschhorn and Hizi, 2010). In
contrast, the endogenous cellular RT has long been overlooked,
despite many clues implicating it in as relevant processes as
embryogenesis and tumorigenesis. Decades after the discoveries
of Baltimore and Temin, a body of evidence has shown that
endogenous RT expression is developmentally modulated:
low levels of RT, if any, are expressed in differentiated non
pathological tissues; increased expression is instead typical of
cells characterized by low differentiation and high proliferation,
e.g., early embryos (for a review see Sciamanna et al., 2011) and
transformed cells (for a review see Sinibaldi-Vallebona et al.,
2011). Overall, that is consistent with the notion that LINE-1
increased expression (Chen et al., 2012a; Rodic´ et al., 2014)
and retroelement mobilization are implicated in tumorigenesis
(Hancks and Kazazian, 2012; Kaer and Speek, 2013).
In contrast to differentiated quiescent cells, tissues and cells
with low differentiation and high proliferation states are sites
of high RT expression and provide permissive contexts for
retrotransposition. Following up on that line, several studies
have pursued RT inhibition in cancer cells, either using non-
nucleoside RT inhibitors (nevirapine and efavirenz;Mangiacasale
et al., 2003; Landriscina et al., 2005; Sciamanna et al., 2005,
2013), or RNA interference (RNAi)-mediated downregulation
of RT-encoding LINE-1 elements (Sciamanna et al., 2005;
Oricchio et al., 2007). In the latter case, the RNAi assays
were carried out using double-stranded siRNA oligonucleotide
targeted against the ORF-1 encoding domain of human full-
length, highly expressed LINE-1s (Brouha et al., 2003). Both the
drug-mediated and the RNAi-mediated approaches to reduce
LINE-1-derived RT were found to reduce proliferation, promote
differentiation and reprogram the global transcription profiles
of coding and non-coding sequences in several cancer cell lines
(human melanoma, glioblastoma, osteosarcoma and prostate,
colon and small cell lung carcinomas). This provided early
evidence for the implication of the LINE-1-encoded RT in
tumorigenesis. The inhibitory effects of efavirenz on LINE-1
reverse transcription and retrotransposition were further tested
in in vitro assays (Dai et al., 2011), and its antiproliferative and
differentiating potential have been recently confirmed in breast
(Patnala et al., 2013) and pancreatic (Hecht et al., 2015) cancer
cell lines. Moreover, efavirenz treatment of mice xenografted
with human tumorigenic cells caused the arrest, or a significant
slow down, of progression of several tumor types in vivo
(Sciamanna et al., 2005). Importantly, RNAi-mediated LINE-
1 downregulation drastically reduced the tumorigenic potential
of human cancer cells in nude mice (Oricchio et al., 2007).
These effects are reversible and, upon discontinuation of RT
inhibitory treatments, tumor cells return to their original de-
differentiated phenotype and unrestrained proliferation capacity
(Sciamanna et al., 2005); these obervations provided initial hints
to an epigenetic role of RT.
The high levels of RT activity found in tumor cells and tissues,
reported by our (Mangiacasale et al., 2003; Gualtieri et al.,
2013) and other laboratories (Patnala et al., 2013), correlate well
with the enhanced rate of retrotransposition observed in many
human tumors, a phenomenon that dramatically contributes
to shape cancer genomes (Iskow et al., 2010; Lee et al., 2012;
Solyom et al., 2012; Shukla et al., 2013; Ewing et al., 2015). In
a MMTV-PyVT transgenic mouse strain (Guy et al., 1992),
whose females spontaneously develop breast carcinoma, a burst
in the copy number of both LINE-1 and SINE B1 elements
was depicted very early at tumor onset; their copy number
further increases along with tumor progression (Gualtieri et al.,
2013). These data converge to indicate that tumors constitute
a highly permissive environment for retrotranscription, yet
do not answer the question of whether overexpression and
amplification of LINE-1 elements act as oncological “drivers” or
as mere “passengers” (Rodic and Burns, 2013). The findings that
pharmacological inhibition of RT is sufficient to reduce cancer
cell proliferation, promote differentiation and antagonize tumor
progression in animal models, similar to the effects obtained by
RNAi-specific downregulation of LINE-1 expression, strongly
support a causative role of LINE-1-encoded RT in tumorigenesis.
In an applied clinical perspective, therefore, RT can be regarded
as a target and RT inhibitors as potential therapeutic agents in a
novel cancer differentiation therapy. Efavirenz has recently been
tested in a phase II trial with metastatic prostate cancer patients,
suggesting that relatively high dosage (over 600mg per day)
may be beneficial as a novel anticancer treatment (Houédé et al.,
2014).
The role of RT encoded by LINE-1 in tumorigenesis is
distinct from that of RT activities produced from the other
two potential sources, i.e., endogenous retroviruses (HERVs)
and telomerase-associated RT (TERT). First, RNAi-mediated
downregulation of HERV-K expression showed negligible effects
on the rate of proliferation and differentiation of cancer cells,
in contrast with the dramatic effects observed after LINE-1-
specific RNAi (Oricchio et al., 2007). Second, inhibitors of
LINE-1 derived RT elicit rapid changes in treated cells in
our experiments (Mangiacasale et al., 2003; Sciamanna et al.,
2005), differently from drugs targeting telomerase, which reduce
cancer cell proliferation after a long tratement (about 120 days;
Damm et al., 2001); these data therefore rule out the possibility
that TERT contributes to the rapid response of cells to RT
inhibitors. It should be noted, however, that LINE-1 RT is critical
for telomere maintenance, given that LINE-1 knockdown in
cancer cells correlates with: (i) reduced length of telomeres,
(ii) decreased telomerase activity, and (iii) decreased telomerase
mRNA level (Aschacher et al., 2016). Together these results
reveal that LINE-1 RT has a functional impact on TERT. Thus,
while TERT is not involved in the changes elicited by inhibitors
targeting the retrotransposon-derived genuine RT, the level of
activity of LINE-1 elements may impact on TERT. These findings
again strengthen the view that LINE-1 RT is a major player in
tumorigenesis.
LINE-1 ORF2-ENCODED RT ACTIVITY IN
CANCER PROGRESSION
The ORF2-encoded RT has been recently assessed for its
suitability as a tumor marker (Gualtieri et al., 2013) in females
of the cancer-prone MMTV-PyVT described above (Guy et al.,
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1992). In these females, breast cancer tissues withdrawn at
different times after birth are representative of progressive
cancer stages. ORF2p cannot be detected in normal breast tissue
by immunohistochemistry (IHC), but increased expression is
triggered very early in tumorigenesis, preceding the appearance
of typical histological alterations and accepted cancer markers
(e.g., Ki67 and epidermal growth factor receptor ERB2); further
upregulation takes place during tumor growth. These findings
correlate well with the notion that hypomethylated LINE-
1 sequences, from which ORF2p is produced, are typical
of cancer genomes and precancerous lesions compared to
their normal tissues counterpart (Miousse and Koturbash,
2015).
The abundant expression of LINE-1 products in preneoplastic
mammary tissues suggests an exploitable tool as a potential
diagnostic biomarker for early cancer detection: the identification
of cancer-prone foci marked by increased RT before the
appearance of recognizable histological alterations, can expand
the window of opportunities for therapeutical intervention,
which can possibly be most effective if associated with the
development of RT inhibitory treatment. Interestingly, the
abundance and subcellular localization of LINE-1 products are
also proposed to have prognostic value in human metastatic
breast cancer (Chen et al., 2012a).
Compelling objectives of “the war on cancer” currently
include the definition of novel early markers identifying cancer-
prone lesions before their spreading, as well as the development
of novel therapeutic approaches in possible replacement of
conventional cytotoxic chemotherapy. In a recent critical
reappraisal, Hanahan (2014) has pointed out that the war on
cancer, if not lost, is certainly not won and has suggested that
therapeutic strategies should avoid fragmenting along multiple,
highly diversified narrow paths targeting many substrates, each
of which is highly selective for a specific cancer. Rather, the
therapeutic “bullets” ought to hit fewer targets shared by a
large spectrum of cancers (Hanahan, 2014). LINE-1 ORF2-
encoded RT would fulfill these criteria, representing, at the
same time, an early diagnostic cancer marker, a worth pursuing
therapeutic target and the driving component of a newly
emerging cancer-promoting mechanism.
THE MOLECULAR BASES OF THE
RT-DEPENDENT CANCER-PROMOTING
MECHANISM
As briefly recalled above, retrotransposition events have had a
fundamental role not only in shaping the genomic landscape,
but also in directing regulatory networks aimed to fine-tune a
variety of genomic functions. Data obtained in the last few years
growingly indicate that the retrotransposon machinery, besides
being a well-known source of genomic variations caused by new
insertions (Böehne et al., 2008; Bourque, 2009), also exerts a
global epigenetic regulatory role on the cellular transcriptome.
LINE-1 ORF2-encoded RT is a new player in this mechanism.
Prompted by the finding that tumor cell lines are endowed
with abundant LINE-1-encoded RT, Sciamanna et al. (2013)
began to address the mechanism through which RT might act
by comparing the global transcription profile of melanoma cells
before and after RT inhibition by microarray analysis. The
results showed that RT inhibition modulates the expression
of a broad range of coding genes, but also long and
small non-coding sequences, including UCRs and miRNAs.
miRNAs actually emerged as crucial components of the RT-
depending mechanism; indeed, a subpopulation, known to be
involved in cell differentiation, cell growth, tumorigenesis and
metastatic progression proved highly responsive to RT inhibition.
Many miRNA-encoding genes are significantly associated with
genomic regions enriched in closely spaced Alu repeats, further
strengthening the link between miRNAs and retrotransposons.
The physical association of pre-miRNA genomic loci with high
density retroelements actually suggests that the latter can exert
a regulatory “position effect” on miRNA expression (Slotkin
and Martienssen, 2007). Experimental evidence supporting an
orchestrating role of the RT enzyme emerged from cesium
chloride density centrifugation analysis of nucleic acids extracted
from melanoma and prostate carcinoma cell lines, harboring
either “native” or efavirenz-inhibited RT: by buoyant density
analysis, LINE-1- and Alu-containing molecules with the density
of DNA:RNA hybrids were selectively identified in tumor cells,
which disappeared upon treatment with efavirenz and were
absent in non-transformed human fibroblasts (Sciamanna et al.,
2013). Thus, the DNA:RNA hybrids are an especially abundant,
if not exclusive, component of cancer cells, generated by reverse
transcription of RNA templates, largely—albeit not exclusively—
provided by LINE-1 and Alu transcripts. These data suggest
that a cancer-promoting RT-dependent mechanism is active
in tumor cells and can be blocked by inhibiting the LINE-1
RT. Based on these data, Sciamanna et al. proposed a model
(Sciamanna et al., 2014) whereby the highly expressed LINE-
1 RT in cancer cells can intercept RNAs and convert them
in RNA:DNA hybrids via reverse transcription. Central to the
model is the RT-dependent production of RNA:DNA hybrids,
associated with altered functional miRNA profiles, observed
under conditions of high LINE-1-derived RT in cancer cells
and modulatable by RT inhibitors. A wealth of data show that
miRNA expression is indeed downregulated in cancer cells,
with profound implications for cell fates (Lu et al., 2005; Gaur
et al., 2007; Jansson and Lund, 2012). A variety of small RNAs,
including 7SL RNA (Ullu and Weiner, 1984), tRNAs (Kaçar
et al., 1992), small nuclear RNAs (Doucet et al., 2015), and
YRNAs (Perreault et al., 2005), are known to act as templates
for reverse transcription in intermediate steps of the genesis of
pseudogenes. It is not unreasonable to hypothesize that miRNA
precursors may also be retrotranscribed. The observation that
the production of hybrid RNA-DNAmolecules is associated with
aberrant miRNA profiles in cancer cells actually suggests that
RT can “subtract” RNA precursors, thus preventing or impairing
the formation of double stranded (ds) RNA dicer substrates
for the biogenesis of mature miRNAs: this would ultimately
contribute to establish favorable conditions for the onset of
cancer phenotypes.
RT inhibition results in restored miRNA biogenesis, likely
re-establishing their regulatory networks, consistent with its
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empirically established capacity to revert the cancer phenotype
(Sciamanna et al., 2013).
In agreement with this idea, a subset of LINE-1-specific
siRNAs, targeting LINE-1 expression and capable to induce
methylation of their promoters, are found to be down-modulated
in breast cancer compared to normal cells (Chen et al.,
2012b). Conversely, LINE-1 inhibition by siRNAs up-modulate
the expression of miRNAs involved in tumor suppression
(Ohms et al., 2014). Taken as a whole, these findings indicate
an orchestrating role of LINE-1-encoded RT in setting a
cancer-permissive cellular state.
Although, the LINE-1 enzymatic machinery preferentially
reverse transcribes its own RNA (Esnault et al., 2000; Wei
et al., 2001; Kulpa and Moran, 2006), the presence of intronless
pseudogenes scattered throughout mammalian genomes points
out that mRNAs transcribed from protein-coding genes are also
substrates for reverse transcription by the endogenous RT (Pink
et al., 2011). This suggests that the RT-depending mechanism,
in addition to targeting miRNAs, can also target several more
RNA classes, coding and non-coding, small- and long-RNAs,
though with a possible preferential bias for those associated with,
or derived from, retroelement sequences. Consistent with this
view, Sciamanna et al. (2013) found that about one third of
the efavirenz-downmodulated miRNAs in melanoma cells are
clustered on chromosome 19 (C19MC) in a locus characterized
by a high density of primate-specific Alu repeats, which were
shown to have co-evolved with miRNAs coding genes (Lehnert
et al., 2009). An independent study also reported that LINE-1
silencing caused a deregulated profile of miRNA expression in
breast cancer cells (Ohms and Rangasamy, 2014).
In summary, LINE-1 expression and small RNA networks
emerge as the balanced components of a RT-depending
regulatory mechanism placed at the intersection between
normally differentiated and transformed non-differentiated
cellular states: when one component raises the other one decays.
It is worth stressing that the partial inactivation of miRNA
function is not an exclusive feature of cancer, but is a
physiological phenomenon, shared with early preimplantation
embryos, a context where again miRNA pathways become
transiently suppressed (Suh et al., 2010). Moreover, miRNA
inactivation is concomitant with a burst of LINE-1 activity in
both tumorigenesis and embryogenesis. In the next paragraph we
discuss this striking analogy and suggest that physiological and
pathological processes have in common the same RT-dependent
mechanism.
THE RT-BASED MECHANISM AS GLOBAL
REGULATOR OF DIFFERENTIATION IN
TUMORIGENESIS AND EMBRYOGENESIS
In prior developmental studies, the presence of LINE-1-encoded
RT activity and protein was assessed in gametes and early
embryos to address the potential role of this enzyme in
embryogenesis. Unexpectedly, Giordano et al. (2000) found
an RT activity in mature murine spermatozoa, providing
the first hint that RT might somehow be involved in early
embryogenesis. The sperm endogenous RT, far from being a
nonfunctional remnant encoded by “genomic parasites,” has
a full enzymatic activity able to reverse transcribe exogenous
RNA molecules, taken up and internalized by spermatozoa,
in cDNA copies that could then be delivered to embryos at
fertilization (Giordano et al., 2000; reviewed in Spadafora, 2008).
Pittoggi et al. (2003) further found that RT is also present
in early embryos and is strictly required for preimplantation
development: indeed, exposing zygotes to RT inhibitor, or
antisense-mediated downregulation of LINE-1 (Beraldi et al.,
2006), both caused a drastic arrest of development at the
two- and four-cell embryo stages with globally altered gene
expression profiles. Interestingly, fertilization activates a reverse
transcription wave in zygotes within a few hours, which then
propagates throughout the first cell division; that is concomitant
with the production of new LINE-1 copies that mostly remain
as non integrated extrachromosomal structures (Vitullo et al.,
2012). Indirect evidence for an embryonic RT activity also emerge
from reports that somatic LINE-1 retrotranspositions occur in
human stem cells (Garcia-Perez et al., 2007; Coufal et al., 2009)
and in very early stages of development in humans (van denHurk
et al., 2007) and rodents using transgenic murine and rat models
(Kano et al., 2009). These findings indicate that the endogenous
RT is active in early stages of embryogenesis, where it appears
to have implications for epigenetic regulation of gene expression
and to be necessary for the unfolding of the developmental
program.
Cancer and embryo developmental studies convergingly point
to the conclusion that an RT-based mechanism is physiologically
activated in early embryogenesis and repressed in differentiated
tissues; its unscheduled re-activation in somatic cells has cancer-
promoting effects, yielding increased cell proliferation and loss
of differentiation, in analogy with embryonic growth. It is a
well-established notion that tumors and embryos share a variety
of cellular, biochemical and molecular features and that genes
typically expressed in embryogenesis, yet silenced in normal
differentiated tissues, are re-expressed in tumors (Ma et al., 2010).
These circumstances support the conclusion that tumorigenesis
often recapitulates developmental patterns (Kaiser et al., 2007).
In this conceptual framework, Spadafora (Spadafora, 2015)
proposed that the RT-dependent mechanism is a source of the
functional analogies shared by the physiological and pathological
processes connecting embryogenesis and tumorigenesis.
THE GENESIS OF CANCER
HETEROGENEITY
The retrotransposon machinery is highly sensitive to stressing
stimuli (Hagan and Rudin, 2002; Terasaki et al., 2013). In
response, LINE-1 expression can be activated at differential levels
in different cells, depending on the nature and the intensity
of endogenous or exogenous stressors. We propose that the
differential activation of RT, including by stress, can generate
the heterogeneously differentiated cell populations that typically
characterize human cancers (Meachem and Morrison, 2013). It
is currently unclear whether the cellular heterogeneity observed
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in cancer reflects the existence of cell populations undergoing a
progressive transformation “trajectory,” initiating as a primary
cancer state and sequentially evolving into metastatic cells, or
whether a broad array of cellular variations simultaneously
arise in a single stress-responding event. Based on the data
discussed above, it is tempting to speculate that the latter is the
case; cells with varying degrees of malignancy—some of which
may confer metastatic capacity—may concomitantly originate
in a single genome-wide burst of stress-activated LINE-1-RT
expression. In this hypothetical model, schematized in Figure 1,
burst(s) of LINE-1 expression, triggered by exogenous and/or
endogenous stimuli in normal cells (in green), would generate
an array of cell populations endowed with various levels of
LINE-1-dependent RT activity (indicated by different shades of
colored cells), coinciding with the emergence of preneoplastic
lesions. We propose that the different levels of LINE-1 activation
correspond to different degrees of cell de-differentiation; in
the process, embryonic regulatory patterns can be reactivated
and induce somatic cells to revert back to embryo-like states
(Kaiser et al., 2007). LINE-1 activation at low levels would
exert modest de-defferentiation effects, while higher levels would
determine a more extensive reactivation of embryonic patterns,
with the ensuing production of more aggressive “embryo-
like” transformed cells. The cell populations concomitantly
originating from the activation of RT expression would then
differentially propagate throughout cancer progression, thus
contributing to cancer heterogeneity. The model represented
in Figure 1 was inspired by the recently proposed “Big Bang”
hypothesis for the genesis of human cancer, in which a single
ancestral event is thought to originate the heterogeneity of
cancer cell populations (Sottoriva et al., 2015), which would then
progress and expand in parallel (Klein, 2009). The simultaneous
genesis of cells with heterogeneous invasive potential would
also offer a possible explanation for the genesis and spreading
of metastatic tumors of unknown primary origin: these are a
relatively rare class of metastatic tumors detected in patients in
which the primary tumor cannot be identified, and account for
3–5% of all cancer diagnoses (Natoli et al., 2011; Stella et al.,
2012).
In more general terms, the model predicts a relatively
minor role for DNA mutations in cancer progression, as cell
transformation is rather viewed as originating from an RT-
mediated reactivation of “embryonic” regulatory circuits mostly
acting at the epigenetic level in differentiated cells (Spadafora,
2015). Although needing further experimental testing, the model
builds on emerging evidence indicating the global reach of RT
onto several RNA classes (Sciamanna et al., 2013; Ohms et al.,
2014; Ohms and Rangasamy, 2014) and is compatible with its
reversible character by modulating RT levels (Sciamanna et al.,
2005).
Retrotransposable elements also clearly impinge on genome
function by generating extensive variations via insertional
mutagenesis. Although large numbers of mutations are identified
by high-throughput sequencing data in cancer contexts, their
role(s) in tumorigenesis is often undefined (Kandoth et al., 2013):
predisposing gene mutations in fact play a documented causative
role only in 5–10% of human cancers (Nagy et al., 2004).
Recent excellent works have reported that the genomes of
different tumor types harbor hundreds of de novo somatic
insertions, selectively found in cancer genomes (Iskow et al.,
2010; Lee et al., 2012; Solyom et al., 2012; Shukla et al., 2013;
Doucet-O’Hare et al., 2015; Ewing et al., 2015; Rodic´ et al., 2015).
Despite of these reports, however, the general implication of
L1 retrotransposition events as either “driver” mutations (i.e.,
with a causative role in tumorigenesis), or as “passengers” (i.e.,
manifesting a consequence of the loss of genome regulation
associated with cell transformation), remains an open question
(Rodic and Burns, 2013). Insertions were documented and were
attributed causative trigger in specific cases; among others, LINE-
1 insertion were found within the c-myc gene (Morse et al., 1988),
or in the tumor-suppressing gene apc (Miki et al., 1992) in breast
and colon carcinoma, respectively; in those instances, LINE-
1 insertions should have an activating (c-myc) or inhibitory
(apc) role, respectively. In a different context, Alu insertions also
result in neurofibromatosis type 1 (Wallace et al., 1991). It is
worth recalling, however, that together LINE-1, Alu and SVA
insertions account only for a marginal contribution (<0.5%) to
the genesis of cancer (Callinan and Batzer, 2006). This leaves
FIGURE 1 | A model for RT-dependent induction of cancer cell heterogeneity. The deregulated expression of LINE-1 elements in somatic cells (green) causes a
burst of RT activity (red flash), which deregulates the transcriptome of individual cells at various levels (represented by different color shades): this originates
heterogeneous cancer cell populations. In the model, cancer cell heterogeneity would therefore set in following the early burst of differentially expressed RT activity in
different cells. Cancer would then progress with the expansion of various cell populations (on the right).
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ample room for non-inserational mechanisms of tumorigenesis
that implicate retrotransposons. In addition, the concept that
new insertions might cause tumorigenesis would be hard to
reconcile with the full reversibility of the “therapeutic” effect
associated with LINE-1 RT inhibition in various cancer cells,
observed in our and other laboratories (Sciamanna et al., 2005;
Oricchio et al., 2007; Patnala et al., 2013). In our model, therefore,
insertional mutagenesis, though not being totally ruled out, plays
aminor role.We believe that most retrotranspositional insertions
observed in many tumors reflect a failure to repress the activity of
retroelements (a frequent failure in cancer), rather than being a
cause of tumorigenesis.
In an extreme view, mutations may often represent a tolerated
consequence of the tumor-associated global deregulation rather
than the cause. The evidence summarized so far suggest
that deregulated RT activity, likely acting in combination
with other key epigenetic processes such as global DNA
hypomethylation and chromatin remodeling, contributes to
shape pro-tumorigenic expression profiles, and thus favors the
phenotypic plasticity and diversity of cancer cells.
CANCER AS A REVERSIBLE
“DEVELOPMENTAL” DISORDER AND
DIFFERENTIATION THERAPY
As discussed above, the non-coding RNA profiles modulated by
RT can globally regulate cell differentiation. Evidence is emerging
that unscheduled reactivation of RT, as occurring in cancer cells,
or its developmentally regulated repression, as in normal cells, are
sufficient to promote cell de-differentiation or, on the contrary,
stabilize the differentiated state, respectively. Tumorigenesis
can be viewed as the erroneous resumption of genome-wide
networks active in embryogenesis and silenced in adult life, and
the differentiation process can be regarded as a sequence of
transient and reversible cellular states in which RT activity is
variably activated. According to this view, cancer would also be
a reversible phenomenon and, as such, potentially modulatable
by RT-inhibitory differentiation-inducing agents. The idea that
the “normal” differentiation program can be restored to cancer
cells, with the loss or attenuation of tumorigenic phenotype,
has inspired much research and clinical work in the last
decades. Perhaps the best known example is the development of
retinoic acid-based differentiation therapy, successfully applied
to treat acute promyelocytic leukemia (APML). Retinoic acid is
a powerful morphogen and differentiating agent and has been
the object of intense studies in the last decades, the outcome of
which cannot be exhaustively discussed here (reviewed by Tang
and Gudas, 2011). Other attempts to apply the same principle
to solid tumors, however, have had more limited results so far
(reviewed by Leszczyniecka et al., 2001; Cruz and Matushansky,
2012). The data obtained from in vitro assays, preclinical tests on
animal models and a recent human trial, converge in viewing the
LINE-1-encoded RT as an effective target for a non-cytotoxic,
differentiation-inducing cancer therapy; RT inihibition appears
to be the common condition sufficent to reverse tumorigenicity
and restore differentiation to a wide variety of cancer cells.
CONCLUSIONS
Growing data undermine the concept of terminal differentiation
as a stably acquired condition, revealing that: (i) differentiation
states should rather be viewed as transient conditions, and (ii)
even in the presence of genomic alterations, epigenetics often
wins over genetics (Lotem and Sachs, 2002). Epigenetic changes
can effectively bypass the genetic alterations associated with,
or caused by, tumorigenesis and reprogram gene expression
profiles, reverting, or mitigating, the malignant phenotypes
of cells. LINE-1-encoded RT is emerging as a key epigenetic
regulator at the intersection between normal and pathological
development. As such, the level of RT activity has the potential to
shift the biological balance of cells in one or the other direction.
In our view, these findings and emerging concepts, besides their
clinical implications, fulfill the early prediction by Temin that
endogenous RT activity plays roles both in normal development,
as in embryogenesis, and in pathologies as such as cancer (Temin,
1971).
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